Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00551161 · ClinicalTrials.gov registry record · Phase 4

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

A Phase 4 study of Alzheimer Disease, sponsored by Northwell Health.

Completed
Registry status
Phase 4
Development phase
12
Enrollment target
1
Study location

NCT00551161 is a Phase 4 study of Alzheimer Disease that has completed, run by Northwell Health. The registered enrollment target is 12 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00551161, a Phase 4 study of Alzheimer Disease, has completed, sponsored by Northwell Health.

COMPLETED
Registry status
Phase 4
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

We are studying subjects with mild to moderate Alzheimer's disease who have been on a stable dose of any cholinesterase inhibitor \[donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)\] for at least 3 months, and have not previously taken memantine (Namenda). This is an open-label study, with magnetic resonance spectroscopy (MRS) as the primary outcome measure, along with neuropsychological testing, and optional lumbar puncture, evaluating patients on their stable dose of a cholinesterase inhibitor over 24 weeks, followed by another 24 weeks on memantine in combination with stable dose of cholinesterase inhibitor. The purpose of this study is to characterize the progression of disease using MRS, cerebrospinal fluid (CSF) biomarkers, and cognitive outcome measures, and to determine whether changes in cognitive function on neuropsychological testing are correlated to changes in MR spectroscopic and/or CSF biomarkers.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG memantine

Study Locations (1)

New York

  • The Litwin-Zucker Research Center - Manhasset

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2007-08
Est. Completion 2011-12
Phase Phase 4

Sponsor

Northwell Health

370 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00551161

The ClinicalTrials.gov registry entry for NCT00551161 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which memantine is the first listed.

NCT00551161 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00551161 about?

NCT00551161 is a clinical study titled "Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease". We are studying subjects with mild to moderate Alzheimer's disease who have been on a stable dose of any cholinesterase inhibitor \[donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)\] for at least 3 months, and have not previously taken memantine (Namenda). This is an open-label ...

What is the current status of trial NCT00551161?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2007-08. Estimated completion is 2011-12.

What conditions does trial NCT00551161 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT00551161?

The interventions under investigation include: memantine (DRUG).

Who is sponsoring clinical trial NCT00551161?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00551161 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.